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'What separates man from the animals is the urge to take medicines . . .' (Sir Williom Osier)
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Fig. 1. Viral resistonce formotion meosured over 48 weeks of
antiretraviral therapy.
Patients should never be commenced an these agents
until they are aware of and committed to this reality.
95% compliance rate (i.e. missing less than 1 dose in 20)
was associated with approximately 20% genotypic
resistance. Missing less than 1dose in 10 conveyed a risk of
genotypic resistance of approximately 55%.
In other words, requirements of patients in terms of
adherence to antiretrovirals are very high. They are much
more stringent than the best adherence levels achievable in
other chronic illnesses, and are absolute in terms of
virological failure being causally linked to clinical decline.
This leads to a vital dictum in HIV medicine:
The relationship between the clinician and the patient must
accommodate the needs for ongoing education, respect,
and support required in such demanding regimens. It is
never necessary to start antiretroviral regimens urgently in
the treatment setting (with the obvious exception of the
post-exposure prophylaxis scenarios of mother-ta-child
The vital role of adherence in the success of ongoing
therapeutic control is well known and well studied. Studies
of other chronic illnesses (for example diabetes, renal
failure, and hypertension) have demonstrated a direct and
causal link between patient adherence to medication and
clinical outcome. In these conditions, average adherence
rates range between 4O'\\J and 60%.... A study by Patterson
et 01' (Rg. 1) demonstrated the degree of viral resistance
formation measured by genotypic analysis over 48 weeks




The advent of highly active antiretroviral therapies (HAARD
in 1995(1996 ushered in a new era in the management of
the HIV pandemic, with new drugs, new strategies, new
vigour from treating clinicians, and enthusiasm on the part
of their patients.' Mortality and morbidity figures dropped
radically,' with associated gains in cost benefits with regard
to macro- and microeconomic costs.' What soon became
evident, however, was the vital importance of patient
adherence with prescribed medication in order to garner
the benefits that were so rapidly becoming available. As a
result, much attention has recently been paid to this aspect
of management. Both clinicians and patients are
recognising the importance of long-term drug
acceptability, availability, and the all-important ability of
patients to sustain such challenging regimens.
:tiny person who takes all his pills 100% of the time, on time, for the rest ofhis life ... is 0 very weird person
(Or Bill O'Brien)
ADHERENCE
What is evident from this study is twofold:
1. Genotypic resistance formation (accurately or less
accurately associated with phenotypic resistance) to any
given antiretroviral regimen seems an inevitability with
time. However, it may be slowed by the degree of
adherence to antiretrovirals maintained by the patient.
2. Resistance to antiretroviral regimens develops at slower
rates with higher compliance with regimens. In this study a
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• 'Minor' (nausea, rash, etc.)
• 'Major' (hepatitis, peripheral neuropathy, etc.)
Pill burden' (Fig. 2)
Food restrictions'




Confidentiality and disclosure issues"
As has already been alluded to, patient preparedness
(initially and ongoing) is the most important factor in
beginning therapy, and vital to ongoing adherence to
antiretroviral agents. Education regarding the illness itself,
the benefits and drawbacks of antiretroviral and other
therapies, and the longstanding nature of such therapy
needs to be exhaustive and ongoing. Patients should be
given sufficient time to consider the personal ramifications
of taking medication lifelong, as well as the associated
issues of confidentiality, disclosure and social stigma that
may or may not impact on their decision. Follow-up
consultations, with family and caregivers if possible, can
assist in this process. This is generally true in all settings,
but particularly if medication is commenced in the
presence of index patient dementia or other illnesses (e.g.
cryptoccocal meningitis) that may impair memory and
mentation. Here carers may assist with medication
administration until such time as the patient is able to take
it independently, in addition to providing ongoing practical
and emotional support.
It makes empiric sense that, given the choice of taking 16
large capsules or 2 small pills to generate equivalent
clinical, virological and immunological success, most
people will opt for the smaller pill burden. It would also
seem logical that, presented with large numbers of pills and
Fig. 2. Plot of virological response by pill burden (r - -0.61,
P- 0.0056) (from Bartlettet al').
transmission prevention, occupational exposure and sexual
exposure such as rape). The treating doctor should restrain
his or her enthusiasm to commence therapy and allay the
patient's anxiety regarding its commencement until both
are prepared to meet the adherence needs of the
subsequent regimens.
Various factors are associated with decreased
adherence to medication regimens.
(The list below is not considered exhaustive.)
Patient adherence (> 90%)
• Counselling and education
• Side-effects




• Genetic deletions (rare)





• Cytochrome P450 interactions




WHAT MAKES REGIMENS FAlL?
Proactive attention to all the above is necessary when
selecting and maintaining antiretroviral regimens. It is also
necessary to revisit this list of reasons for drug failure at
each stage of the process. Acting to prevent certain of the
problems and side-effects that may hamper adherence, and
to explain to and inform patients in this regard, generally
makes dealing with adherence to these protocols a lot
easier for both doctor and patient For example, regimens
containing agents that may cause nausea (such as AZT or
ritonavir) may be made easier to tolerate by the use of
prophylactic antinauseants. (preferably utilising centrally
acting agents such as cyclizine or buclizine). Likewise, the
risk of diarrhoea with agents such as nelfinavir should be
highlighted before the patient begins to take the drug.
Treatment of this side-effect can then be effected rapidly,
diminishing patient discomfort, and encouraging high
adherence levels.
FACILITATING EASE OF ADMINISTRATION OF ARV
REGIMENS
capsules to take on a continuous basis, as opposed to
having to take only small numbers, patients are more likely
to remain adherent to the latter regimen. Bartlett' has
demonstrated this with virological data from clinical trials,
showing that increasing pill burden is negatively correlated
with sustained undetectable [< 50 copies HIV-l RNA/ml]
virological response.
FOOO RESTRICllONS
When an antiretroviral regimen is further complicated by
food restrictions, 'or example the requirement 0 dosing on
an empty stomach for buffered didanosine preparations,
and the separation of buffered didanosine 'rom indinavir
preparations in the same regimen (both requiring empty-
stomach dosing), the potential for missing doses increases,
as does the risk of long-term intolerance of the regimen as
a whole.
The advent of enteric-coated didanosine (not yet available
in southern Africa) has removed the need for food
restrictions with this agent, allowing it to be taken with
other antiretrovirals and other medications.
The use of 'boosted' protease regimens (inhibiting
cytochrome 3A4 by the use of low-dose ritonavir in order
to increase serum levels or serum half-lives of other
protease inhibitors) has similarly altered food restrictions
with many of this class of agents, and has also changed
dosing frequencies.
DOSING FREQUENCY
Taking medication on a rigid schedule is made easier by
Iimi ing he frequency of dosing. In trials of
antihypertensives adherence was improved from 59 on 3
imes a day dosing 084% on once-daily regimens:: Data
'rom he Somerset Hospital HIV Clinical Trial Unit': have
shown that table dosing complexity [as measured by pill
counts) correlates with decreased adherence to
antiretroviral regimens. Three times a day regimens are
shown by the same group [Q be statistically correlated with
poorer adherence outcomes than twice aday regimens. The
same adherence benefit has been seen in 'switch regimens',
where 3 times a day protease inhibitor containing regimens
are converted to twice a day regimens by the addition of
ritonivir,'J
SIDE-EFFECT PROFILES AND ADVERSE DRUG
INTERACTIONS
As has been mentioned above, paying attention to
minimising side-effect profiles of individual agents and
combinations of drugs is vital to the success 0'
antiretroviral regirrens. Some sioe-effects cannot be
avoided, but may be successfully treated with simple
remedies. Medium- to long-term side-effect profiles are
becoming increasingly predictable, allowing for regimen
planning that minimises or prevents overlapping toxicities
and side-effects. Ongoing support and education in this
regard empowers the patient to take control of such
events, demystifying them and allowing for earlier
reporting of adverse events.
Similarly, as knowledge increases regarding adverse drug
reactions [particularly when interac ions with
antirerrovirals generate or worse side-effect profiles), the
clinician is enabled to select concomi ant medications
wisely and appropriately. The patient's knowledge of the
'aer Ihat interactions may occur, in conjunction with easy
access to the clinician to discuss proposed additions to the
medication regimen (for example OTe agents, traditional
and herbal medications or drugs prescribed by another
practitioner), can diminish the chance of such events
occurring.
Minimising adverse events in these ways improves the
tolerability of antiretroviral regimens, in turn leading to
increased adherence and improved sustained virological
control.
ASSISTING WITH ADHERENCE TO ANTIRETROVIRALS
Improving adherence is an ongoing exercise, founded
equally in the empowerment of the patient and the
expertise and attention of the clinician. Regimens should
only be commenced when the patient is fully prepared to
commit to them, and the physician to the ongoing
management of the patient.
Attention should be paid, on an ongoing basis, to:
• Patient-rela ed issues
• Drug regimen complexity
• Dosing regimens requiring food restrictions
• Side-effect profiles and concomitant medication
interactions.
Finally, iI is vital never to underestimate Ihe role of the
doctor-patient relationship and the importance of family
and friends in maintaining and improving adherence.
Taking medications on a strict regimen for the rest of one's
life is greatly eased by having a network of supportive
persons to assist one.
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